Publication Build: This will be filled in by the publication tooling
@prefix fhir: <http://hl7.org/fhir/> .
@prefix loinc: <https://loinc.org/rdf/> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
# - resource -------------------------------------------------------------------
a fhir:Task ;
fhir:nodeRole fhir:treeRoot ;
fhir:id [ fhir:v "PGxRecEx01"] ; #
fhir:meta [
( fhir:profile [
fhir:v "http://hl7.org/fhir/uv/genomics-reporting/StructureDefinition/followup-recommendation"^^xsd:anyURI ;
fhir:link <http://hl7.org/fhir/uv/genomics-reporting/StructureDefinition/followup-recommendation> ] )
] ; #
fhir:text [
fhir:status [ fhir:v "generated" ] ;
fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: Task PGxRecEx01</b></p><a name=\"PGxRecEx01\"> </a><a name=\"hcPGxRecEx01\"> </a><a name=\"PGxRecEx01-en-US\"> </a><p><b>status</b>: Requested</p><p><b>intent</b>: proposal</p><p><b>code</b>: <span title=\"Codes:{http://loinc.org LA26421-0}\">Consider alternative medication</span></p><p><b>description</b>: For clopidogrel, individuals with this diplotype are expected to have significantly reduced platelet inhibition, increased residual platelet aggregation and increased risk for adverse cardiovascular events in response to clopidogrel. Alternative antiplatelet therapy (if no contraindication) is recommended. Refer to current guidelines for dosage and recommendations at https://cpicpgx.org/guidelines/guideline- for-clopidogrel-and-cyp2c19/</p><p><b>for</b>: <a href=\"Patient-CGPatientExample01.html\">Adam B. Everyman Male, DoB: 1951-01-20 ( Medical Record Number: m123 (use: usual, ))</a></p><p><b>reasonReference</b>: <a href=\"Observation-TxImp01.html\">Poor metabolizer</a></p></div>"
] ; #
fhir:status [ fhir:v "requested"] ; #
fhir:intent [ fhir:v "proposal"] ; #
fhir:code [
( fhir:coding [
a loinc:LA26421-0 ;
fhir:system [ fhir:v "http://loinc.org"^^xsd:anyURI ] ;
fhir:code [ fhir:v "LA26421-0" ] ;
fhir:display [ fhir:v "Consider alternative medication" ] ] )
] ; #
fhir:description [ fhir:v "For clopidogrel, individuals with this diplotype are expected to have significantly reduced platelet inhibition, increased residual platelet aggregation and increased risk for adverse cardiovascular events in response to clopidogrel. Alternative antiplatelet therapy (if no contraindication) is recommended. Refer to current guidelines for dosage and recommendations at https://cpicpgx.org/guidelines/guideline- for-clopidogrel-and-cyp2c19/"] ; #
fhir:for [
fhir:reference [ fhir:v "Patient/CGPatientExample01" ]
] ; #
fhir:reasonReference [
fhir:reference [ fhir:v "Observation/TxImp01" ] ;
fhir:display [ fhir:v "Poor metabolizer" ]
] . #
IG © 2022+ HL7 International / Clinical Genomics. Package hl7.fhir.uv.genomics-reporting#3.0.0 based on FHIR 4.0.1. Generated 2024-12-12
Links: Table of Contents |
QA Report
| Version History |
|
Propose a change